Oncology CAR-T has a geography problem The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.
Oncology Expanding the haematology toolkit: Insights and operational ... With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.
News BMS's Breyanzi is first CAR-T for marginal zone lymphoma Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.
Oncology Breaking barriers to CAR T-cell therapy: The vision for expa... Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.
R&D Purity, potency, and safety – affordably – in stem cell ther... In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s
News JPM: Precision Bio continues offload of CAR-T rights Precision BioSciences has agreed to a second licensing deal for its ‘off-the-shelf’ CAR-T therapy azer-cel, as it switches focus to developing in vivo applications of its
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
